ArticleInternational journal of molecular sciences2020
High Expression of miR-34a Associated with Less Aggressive Cancer Biology but Not with Survival in Breast Cancer.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 44 citations in OpenAlex.
- The role of circulating MiR-34a-5p and MiR-let7a-5p as a diagnostic tumor markers in breast cancer a cross-sectional analysis.Molecular biology reports · 2026Article
- Analysis of the Expression Patterns of Tumor Necrosis Factor Alpha Signaling Pathways and Regulatory MicroRNAs in Astrocytic Tumors.International journal of molecular sciences · 2025Article
- Dual Regulation and Clinical Application of miR-34 in Virus-Related Tumors Through Anti-Viral Immunity and Tumor Suppression.Drug design, development and therapy · 2025Review
- Molecular Signature of miR-34a/NEAT-1/p53 Axis in Mycosis Fungoides.Dermatology research and practice · 2024Article
- Review
- Metastasis Inhibition.International journal of molecular sciences · 2023Article
- Review
- Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?Discover oncology · 2022Article
- Low RUFY3 expression level is associated with lymph node metastasis in older women with invasive breast cancer.Breast cancer research and treatment · 2022Article
- Intratumoral lymphatic endothelial cell infiltration reflecting lymphangiogenesis is counterbalanced by immune responses and better cancer biology in the breast cancer tumor microenvironment.American journal of cancer research · 2022Article
- Intratumoral density of regulatory T cells is a predictor of host immune response and chemotherapy response in colorectal cancer.American journal of cancer research · 2022Article
- MicroRNA-34a Promotes Ischemia-Induced Cardiomyocytes Apoptosis through Targeting Notch1.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- An immune-inflamed tumor microenvironment as defined by CD8 score is associated with favorable oncologic outcomes in hepatocellular carcinoma independent of measures of tumor mutational burden.American journal of cancer research · 2022Article
- Low adipocyte hepatocellular carcinoma is associated with aggressive cancer biology and with worse survival.American journal of cancer research · 2022Article
- High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer.American journal of cancer research · 2022Article
- Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer.Scientific reports · 2021Article
- Urine as a Source of Liquid Biopsy for Cancer.Cancers · 2021Review
- Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment.Cancers · 2021Article
- Article
- Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC).American journal of cancer research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most breast cancer (BC) patients succumb to metastatic disease. MiR-34a is a well-known tumor suppressive microRNA which exerts its anti-cancer functions by playing a role in p53, apoptosis induction, and epithelial-mesenchymal transition (EMT) suppression. Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas (TCGA) cohorts were used to test our hypothesis that miR-34a high BCs translate to less aggressive cancer biology and better survival in large cohorts. There was no association between miR-34a expression levels and clinicopathological features of BC patients except for HER2 positivity. MiR-34a high expressing tumors were associated with lower Nottingham pathological grades and lower MKI67 expression. In agreement, high miR-34a tumors demonstrated lower GSVA scores of cell cycle and cell proliferation-related gene sets. High miR-34a tumors enriched the p53 pathway and apoptosis gene sets. Unexpectedly, high miR-34a tumors also associated with elevated EMT pathway score and ZEB1 and two expressions. MiR-34a expression did not associate with any distant metastasis. Further, high miR-34a tumors did not associate with better survival compared with miR-34a low tumors. In conclusion, the clinical relevance of miR-34a high expressing tumors was associated with suppressed cell proliferation, enhanced p53 pathway and apoptosis, but enhanced EMT and these findings did not reflect better survival outcomes in large BC patient cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.